208 related articles for article (PubMed ID: 33673653)
1. Investigation of the Impact of
He Q; Bu F; Zhang H; Wang Q; Tang Z; Yuan J; Lin HS; Xiang X
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33673653
[TBL] [Abstract][Full Text] [Related]
2. Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach.
He Q; Bu F; Wang Q; Li M; Lin J; Tang Z; Mak WY; Zhuang X; Zhu X; Lin HS; Xiang X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562875
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.
Zhang H; Bu F; Li L; Jiao Z; Ma G; Cai W; Zhuang X; Lin HS; Shin JG; Xiang X
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):331-340. PubMed ID: 28945011
[TBL] [Abstract][Full Text] [Related]
4. Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A.
Zheng A; Yang D; Pan C; He Q; Zhu X; Xiang X; Ji P
Eur J Pharm Sci; 2024 May; 196():106757. PubMed ID: 38556066
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule.
Fan J; Chen L; Lu X; Li M; Zhu L
AAPS PharmSciTech; 2019 Jul; 20(6):247. PubMed ID: 31286321
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide.
Chen L; Ji N; Zhang M; Chen W
Recent Pat Anticancer Drug Discov; 2022; 17(2):195-203. PubMed ID: 34758719
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetic study of tacrolimus and
Qu J; Bian R; Liu B; Chen J; Zhai J; Teng F; Guo W; Wei H
Front Pharmacol; 2022; 13():956166. PubMed ID: 36188616
[No Abstract] [Full Text] [Related]
8. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
Gong F; Hu H; Ouyang Y; Liao ZZ; Kong Y; Hu JF; He H; Zhou Y
Toxicol Appl Pharmacol; 2023 May; 466():116475. PubMed ID: 36931438
[TBL] [Abstract][Full Text] [Related]
9. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats.
Wei H; Tao X; Di P; Yang Y; Li J; Qian X; Feng J; Chen W
Drug Metab Dispos; 2013 Jul; 41(7):1398-403. PubMed ID: 23628674
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
12. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.
Adiwidjaja J; Boddy AV; McLachlan AJ
Br J Clin Pharmacol; 2020 Oct; 86(10):2080-2094. PubMed ID: 32250458
[TBL] [Abstract][Full Text] [Related]
13. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.
Emoto C; Fukuda T; Venkatasubramanian R; Vinks AA
Br J Clin Pharmacol; 2015 Dec; 80(6):1438-46. PubMed ID: 26256674
[TBL] [Abstract][Full Text] [Related]
14. A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients.
Pei L; Li R; Zhou H; Du W; Gu Y; Jiang Y; Wang Y; Chen X; Sun J; Zhu J
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004558
[TBL] [Abstract][Full Text] [Related]
15. A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype.
Itohara K; Yano I; Tsuzuki T; Uesugi M; Nakagawa S; Yonezawa A; Okajima H; Kaido T; Uemoto S; Matsubara K
CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):587-595. PubMed ID: 31087501
[TBL] [Abstract][Full Text] [Related]
16. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
Chen X; Wang DD; Xu H; Li ZP
Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
[TBL] [Abstract][Full Text] [Related]
17. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients.
Hong E; Carmanov E; Shi A; Chung PS; Rao AP; Forrester K; Beringer PM
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242680
[TBL] [Abstract][Full Text] [Related]
18. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
19. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.
Dai Y; Hebert MF; Isoherranen N; Davis CL; Marsh C; Shen DD; Thummel KE
Drug Metab Dispos; 2006 May; 34(5):836-47. PubMed ID: 16501005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
